Health secretary Robert F. Kennedy Jr. has installed John Gaitanis, a pediatric neurologist, as the new chair of the Interagency Autism Coordinating Committee. That committee helps the federal government decide how to allocate roughly $2 billion in autism research funding. The appointment raises a question about how the federal government decides which research gets money: whether the person steering the ship has ties to products that stand to benefit from it.
Gaitanis’s Background
Gaitanis is a pediatric neurologist. He recently began a stint at the National Institutes of Health’s child health institute. His most notable work has been with Meadow Biosciences, the telehealth startup he co-founded, which focuses on helping autistic kids access leucovorin — a drug that President Trump touted during a news conference last year, even though the clinical evidence that it helps improve speech is sparse.
He is best known for co-founding Meadow Biosciences. The company is a telehealth startup centered around helping autistic kids access leucovorin. That drug was promoted by President Trump during a news conference, despite the fact that the evidence that it helps improve speech is sparse.
The Autism Committee
The Interagency Autism Coordinating Committee is a federal body that helps decide how to allocate roughly $2 billion in autism research funding. Its role is to coordinate across government agencies on research priorities. The committee’s work is significant because it shapes what gets studied and funded.
Sylvia Fogel’s Exit
Sylvia Fogel served as the committee’s chair before Gaitanis. She got into testy exchanges with other committee members during her tenure. She pushed for doubling autism research funding and oversaw the creation of a new strategic plan.
That plan ditches genetic research in favor of investigations into environmental causes, including vaccines. The committee’s work is significant because it shapes what gets studied and funded.
Kennedy’s Decision
Kennedy installed Gaitanis in the chair. The source does not describe whether an ethics check process was announced or not.
The committee’s work is significant because it shapes what gets studied and funded.
Leucovorin and Trump’s Promotion
Leucovorin is the drug at the center of the controversy. President Trump promoted it during a news conference, even though the clinical evidence that it helps improve speech is sparse. The promotion drew attention to the drug, but the evidence base remains thin.
The Ethics Check Question
The appointment raises a question that sits at the heart of how the federal government decides which research gets money: whether the person steering the ship has ties to products that stand to benefit from it.
The committee’s work is significant because it shapes what gets studied and funded. A chair with ties to a specific product could influence which research is prioritized.
What Comes Next
The committee will now operate under Gaitanis’s leadership. Kennedy installed Gaitanis in the chair. The source does not describe whether an ethics check process was announced or not.
The appointment is notable because of his ties to Meadow Biosciences and the leucovorin it sells.
The Broader Picture
The appointment comes at a moment when the federal government is grappling with how to allocate research funding. The autism committee plays a direct role in that process. The committee’s work is significant because it shapes what gets studied and funded.
The Key Facts
| Fact | Detail |
|---|---|
| New chair | John Gaitanis, pediatric neurologist |
| Previous chair | Sylvia Fogel |
| Committee | Interagency Autism Coordinating Committee |
| Funding | Roughly $2 billion |
| Drug in question | Leucovorin |
| Promoter | President Trump |
| Evidence base | Sparse |
The appointment of Gaitanis as chair of the Interagency Autism Coordinating Committee is notable because of his ties to Meadow Biosciences and the leucovorin it sells. The committee’s work is significant because it shapes what gets studied and funded. A chair with ties to a specific product could influence which research is prioritized.
Source material: “New federal autism committee head has financial ties to leucovorin,” STAT.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.